Viamet raises $18 million

Viamet Pharmaceuticals Inc. (Morrisville, N.C.) raised $18 million in a series B round led by Novartis Option Fund and Lilly Ventures. Existing investors Intersouth Partners; Hatteras Venture Partners; Lurie Investment Fund; and Astellas Venture Management also participated. Viamet is developing metalloenzyme inhibitors for infectious diseases and cancer. It expects to begin Phase I testing in 3Q10. ...